
TY  - JOUR
TI  - Abstracts (359 - 460)
JO  - American Journal of Transplantation
VL  - 3
IS  - s5
SN  - 1600-6135
UR  - https://doi.org/10.1034/j.1600-6143.3.s5.015b.x
DO  - doi:10.1034/j.1600-6143.3.s5.015b.x
SP  - 359
EP  - 460
PY  - 2003
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Transplant International
VL  - 18
IS  - s1
SN  - 0934-0874
UR  - https://doi.org/10.1111/j.1432-2277.2005.18s1_004.x
DO  - doi:10.1111/j.1432-2277.2005.18s1_004.x
SP  - 59
EP  - 249
PY  - 2005
ER  - 

TY  - JOUR
C7  - 18438
TI  - ABSTRACTS
JO  - Journal of the International AIDS Society
VL  - 15
IS  - S3
SN  - 1758-2652
UR  - https://doi.org/10.7448/IAS.15.5.18438
DO  - doi:10.7448/IAS.15.5.18438
SP  - 18438
PY  - 2012
ER  - 

TY  - JOUR
TI  - Abstracts for the Annual Scientific Meeting of the Thoracic Society of Australia & New Zealand ‘Frontiers of Respiratory Medicine’ 15–18 March 1998, Adelaide, South Australia
JO  - Cell Proliferation
VL  - 39
IS  - 5
SN  - 0960-7722
UR  - https://doi.org/10.1111/j.1365-2184.2006.00393.x
DO  - doi:10.1111/j.1365-2184.2006.00393.x
SP  - 339
EP  - 378
PY  - 2006
ER  - 

TY  - JOUR
TI  - Neuroglia in Neurological Diseases
JO  - Respirology
JA  - Verkhratsky/Glial Physiology and Pathophysiology
VL  - 5
IS  - S2
SN  - 1323-7799
UR  - https://doi.org/10.1111/resp.2000.5.s2.a77
DO  - doi:10.1111/resp.2000.5.s2.a77
SP  - A77
EP  - A133
KW  - alexander disease (AxD)
KW  - autistic disorders
KW  - CNS oedema
KW  - ischaemia
KW  - metabolic disorders
KW  - neuroglia
KW  - neurological diseases
PY  - 2000
AB  - Summary Neurological diseases are disorders of the brain, spinal cord and the nerves. Alexander disease (AxD) is the only known example of primary astrogliopathology, being caused by the mutation of astroglia-specific gene. The disruption of blood flow can be caused either by blood vessel rupture or by a restriction of blood supply to the brain or parts of the brain, commonly referred to as brain ischaemia. Astrocytes are the most ischaemia-resistant elements of neural circuits. They are powerful scavengers of Reactive Oxygen Species (ROS). The chapter focuses on neurodegenerative diseases. Gliomas are tumours of the nervous system that develop from glial cells. Glioma cells can undergo substantial shrinkage, which helps them to attain an elongated shape and thus penetrate into narrow interstitial compartments. The majority of therapeutic approaches currently in clinical use target neurones, but it seems likely that future therapeutic efforts may benefit by a stronger focus on neuroglia.
ER  - 

C7  - pp. 453-512
TI  - 2014 ACVIM Forum Research Report Program
SN  - 9780470978528
UR  - https://doi.org/10.1002/9781118402061.ch10
DO  - doi:10.1002/9781118402061.ch10
SP  - 453-512
PY  - 2000
ER  - 

TY  - JOUR
TI  - Symposia
JO  - Journal of Veterinary Internal Medicine
VL  - 28
IS  - 4
SN  - 9780470978528
UR  - https://doi.org/10.1111/jvim.12375
DO  - doi:10.1111/jvim.12375
SP  - 1346
EP  - 1374
PY  - 2014
ER  - 

TY  - JOUR
TI  - Poster abstracts
JO  - Fundamental & Clinical Pharmacology
VL  - 18
IS  - s1
SN  - 9780470978528
UR  - https://doi.org/10.1111/j.1472-8206.2004.00259.x
DO  - doi:10.1111/j.1472-8206.2004.00259.x
SP  - 5
EP  - 22
PY  - 2004
ER  - 

TY  - JOUR
AU  - Jeon, Min-Tae
AU  - Moon, Gyeong Joon
AU  - Kim, Sehwan
AU  - Choi, Minji
AU  - Oh, Yong-Seok
AU  - Kim, Dong Woon
AU  - Kim, Hyung-Jun
AU  - Lee, Kea Joo
AU  - Choe, Youngshik
AU  - Ha, Chang Man
AU  - Jang, Il-Sung
AU  - Nakamura, Michiko
AU  - McLean, Catriona
AU  - Chung, Won-Suk
AU  - Shin, Won-Ho
AU  - Lee, Seok-Geun
AU  - Kim, Sang Ryong
C8  - 2019-BJP-0247-RP.R2
TI  - Neurotrophic interactions between neurons and astrocytes following AAV1-Rheb(S16H) transduction in the hippocampus in vivo
JO  - Transfusion Alternatives in Transfusion Medicine
JA  - Br J Pharmacol
VL  - 10
IS  - s1
SN  - 9780470978528
UR  - https://doi.org/10.1111/j.1778-428X.2008.00098.x
DO  - doi:10.1111/j.1778-428X.2008.00098.x
SP  - 20
EP  - 50
PY  - 2008
AB  - Background and Purpose We recently reported that AAV1-Rheb(S16H) transduction could protect hippocampal neurons through the induction of brain-derived neurotrophic factor (BDNF) in the rat hippocampus in vivo. It is still unclear how neuronal BDNF produced by AAV1-Rheb(S16H) transduction induces neuroprotective effects in the hippocampus and whether its up-regulation contributes to the enhance of a neuroprotective system in the adult brain. Experimental Approach To determine the presence of a neuroprotective system in the hippocampus of patients with Alzheimer's disease (AD), we examined the levels of glial fibrillary acidic protein, BDNF and ciliary neurotrophic factor (CNTF) and their receptors, tropomyocin receptor kinase B (TrkB) and CNTF receptor α(CNTFRα), in the hippocampus of AD patients. We also determined whether AAV1-Rheb(S16H) transduction stimulates astroglial activation and whether reactive astrocytes contribute to neuroprotection in models of hippocampal neurotoxicity in vivo and in vitro. Key Results AD patients may have a potential neuroprotective system, demonstrated by increased levels of full-length TrkB and CNTFRα in the hippocampus. Further AAV1-Rheb(S16H) transduction induced sustained increases in the levels of full-length TrkB and CNTFRα in reactive astrocytes and hippocampal neurons. Moreover, neuronal BDNF produced by Rheb(S16H) transduction of hippocampal neurons induced reactive astrocytes, resulting in CNTF production through the activation of astrocytic TrkB and the up-regulation of neuronal BDNF and astrocytic CNTF which had synergistic effects on the survival of hippocampal neurons in vivo. Conclusions and Implications The results demonstrated that Rheb(S16H) transduction of hippocampal neurons could strengthen the neuroprotective system and this intensified system may have a therapeutic value against neurodegeneration in the adult brain.
ER  - 

TY  - JOUR
TI  - Poster
JO  - British Journal of Pharmacology
JA  - J Clin Periodontol
VL  - 177
IS  - 3
SN  - 9780470978528
UR  - https://doi.org/10.1111/bph.14882
DO  - doi:10.1111/bph.14882
SP  - 668
EP  - 686
PY  - 2020
ER  - 

TY  - JOUR
TI  - ORTHOPAEDIC SURGERY AND SPORTS MEDICINE
JO  - Journal of Clinical Periodontology
VL  - 42
IS  - S17
SN  - 9780470978528
UR  - https://doi.org/10.1111/jcpe.12399
DO  - doi:10.1111/jcpe.12399
SP  - 64
EP  - 442
PY  - 2015
ER  - 

TY  - JOUR
TI  - RHEUMATOID ARTHRITIS – CLINICAL ASPECTS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470978528
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_18.x
DO  - doi:10.1111/j.1479-8077.2006.00199_18.x
SP  - A101
EP  - A108
PY  - 2006
ER  - 

TY  - JOUR
AU  - Mastellos, Dimitrios C.
AU  - Yancopoulou, Despina
AU  - Kokkinos, Petros
AU  - Huber-Lang, Markus
AU  - Hajishengallis, George
AU  - Biglarnia, Ali R.
AU  - Lupu, Florea
AU  - Nilsson, Bo
AU  - Risitano, Antonio M.
AU  - Ricklin, Daniel
AU  - Lambris, John D.
TI  - Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention
JO  - APLAR Journal of Rheumatology
JA  - Eur J Clin Invest
VL  - 9
IS  - s1
SN  - 9780470978528
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_23.x
DO  - doi:10.1111/j.1479-8077.2006.00199_23.x
SP  - A167
EP  - A188
KW  - clinical translation
KW  - complement-based drug design
KW  - compstatin
KW  - Cp40
KW  - nonhuman primate models
KW  - peptidic C3 inhibitors
PY  - 2006
AB  - Abstract There is a growing awareness that complement plays an integral role in human physiology and disease, transcending its traditional perception as an accessory system for pathogen clearance and opsonic cell killing. As the list of pathologies linked to dysregulated complement activation grows longer, it has become clear that targeted modulation of this innate immune system opens new windows of therapeutic opportunity for anti-inflammatory drug design. Indeed, the introduction of the first complement-targeting drugs has reignited a vibrant interest in the clinical translation of complement-based inhibitors. Compstatin was discovered as a cyclic peptide that inhibits complement activation by binding C3 and interfering with convertase formation and C3 cleavage. As the convergence point of all activation pathways and a molecular hub for crosstalk with multiple pathogenic pathways, C3 represents an attractive target for therapeutic modulation of the complement cascade. A multidisciplinary drug optimization effort encompassing rational ?wet? and in silico synthetic approaches and an array of biophysical, structural and analytical tools has culminated in an impressive structure-function refinement of compstatin, yielding a series of analogues that show promise for a wide spectrum of clinical applications. These new derivatives have improved inhibitory potency and pharmacokinetic profiles and show efficacy in clinically relevant primate models of disease. This review provides an up-to-date survey of the drug design effort placed on the compstatin family of C3 inhibitors, highlighting the most promising drug candidates. It also discusses translational challenges in complement drug discovery and peptide drug development and reviews concerns related to systemic C3 interception.
ER  - 

TY  - JOUR
TI  - ALLIED HEALTH PROFESSIONALS
JO  - European Journal of Clinical Investigation
VL  - 45
IS  - 4
SN  - 9780470978528
UR  - https://doi.org/10.1111/eci.12419
DO  - doi:10.1111/eci.12419
SP  - 423
EP  - 440
PY  - 2015
ER  - 

TY  - JOUR
TI  - EPIDEMIOLOGY OF RHEUMATIC DISEASES
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470978528
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_1.x
DO  - doi:10.1111/j.1479-8077.2006.00199_1.x
SP  - A21
EP  - A25
PY  - 2006
ER  - 

TY  - JOUR
TI  - SCLERODERMA AND RELATED SYNDROMES
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470978528
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_10.x
DO  - doi:10.1111/j.1479-8077.2006.00199_10.x
SP  - A54
EP  - A66
PY  - 2006
ER  - 

TY  - JOUR
TI  - DIAGNOSTICS AND IMAGING PROCEDURES
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470978528
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_26.x
DO  - doi:10.1111/j.1479-8077.2006.00199_26.x
SP  - A225
EP  - A230
PY  - 2006
ER  - 

TY  - JOUR
TI  - EDUCATION
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470978528
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_8.x
DO  - doi:10.1111/j.1479-8077.2006.00199_8.x
SP  - A45
EP  - A51
PY  - 2006
ER  - 

TY  - JOUR
TI  - CELL RECEPTOR-LIGAND INTERACTION, SIGNALING AND ACTIVATION
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470978528
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_9.x
DO  - doi:10.1111/j.1479-8077.2006.00199_9.x
SP  - A52
EP  - A54
PY  - 2006
ER  - 

TY  - JOUR
TI  - CELL RECEPTOR‐LIGAND INTERACTION, SIGNALING AND ACTIVATION
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470978528
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_6.x
DO  - doi:10.1111/j.1479-8077.2006.00199_6.x
SP  - A39
EP  - A39
PY  - 2006
ER  - 
